Berberine Inhibits Migration and Apoptosis of Rat Podocytes in Diabetic Nephropathy via the Novel lncRNA LOC102549726 Related Pathway
Phytotherapy Research · 2025
DOI: 10.1002/ptr.8452 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytotherapy Research, 2025. Verfasst von Chen Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, the First Affiliated Hospital of University of USTC, Division of Life Sciences and Medicine, University of Science and Techno…. Hauptthemen laut MEDLINE: Podocytes, RNA, Long Noncoding, Diabetic Nephropathies, Berberine. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Scientific Research Project of Anhui Provincial Education Department.
Abstract (Originalsprache)
Background
Diabetic nephropathy (DN) stands as one of the most severe complications of diabetes. Podocytes injury, particularly its attachment to the lateral glomerular basement membrane, serves as a crucial indicator of DN. Growing evidence suggests that berberine (BBR) can mitigate the onset and progression of DN. However, the molecular mechanisms through which BBR exerts its beneficial effects in the treatment of DN remain incompletely elucidated.
Purpose
To explore the underlying mechanisms by which BBR exerts its therapeutic effects in DN.
Methods
High‐throughput lncRNA sequencing on the renal cortex of both the DN model group and the normal SD group was performed to dig for differentially expressed lncRNAs. The expression of LOC102549726 was evaluated using qPCR. The biological functions of LOC102549726 were analyzed in podocyets and DN rats. The bioinformatics techniques, qPCR and WB were used to explore the potential molecular mechanisms.
Results
We found that lncRNA LOC102549726 was highly expressed in renal cortex of DN rats and podocytes subjected to high glucose conditions. Silencing LOC102549726 inhibited migration and apoptosis of podocytes. Mechanistically, LOC102549726 was identified as a facilitator of the expression of EGF and forkhead box O1 (FOXO1). BBR, a known therapeutic agent for DN, exhibited the ability to diminish the level of LOC102549726, EGF and FOXO1 in both DN rats and podocytes.
Conclusion
Our findings suggested that BBR suppresses migration and apoptosis of podocytes in DN through targeting the LOC102549726/EGF/FOXO1 axis. This sheds light on a potential therapeutic avenue for mitigating the impact of DN on podocyte function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, the First Affiliated Hospital of University of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China (USTC), Hefei, China.
- Anhui Provincial Key Laboratory of Precision Pharmaceutical Preparations and Clinical Pharmacy, Hefei, China.
ORCID-Profile: Liqin Tang
Förderung
- National Natural Science Foundation of China
- Scientific Research Project of Anhui Provincial Education Department
Zitieren
APA
Wang, C., Wu, H., Xie, Y., Wang, J., Huang, L., Ni, X., Deng, S., Zhang, Y., Chen, X., Zhang, H., Yuan, S., & Tang, L. (2025). Berberine Inhibits Migration and Apoptosis of Rat Podocytes in Diabetic Nephropathy via the Novel lncRNA LOC102549726 Related Pathway. Phytotherapy Research. https://doi.org/10.1002/ptr.8452
Vancouver
Wang C, Wu H, Xie Y, Wang J, Huang L, Ni X, et al. Berberine Inhibits Migration and Apoptosis of Rat Podocytes in Diabetic Nephropathy via the Novel lncRNA LOC102549726 Related Pathway. Phytotherapy Research. 2025. doi:10.1002/ptr.8452
BibTeX
@article{Wang2025,
author = {Wang, Chen and Wu, Hao and Xie, Yongsheng and Wang, Jiajia and Huang, Lingzhi and Ni, Xiayun and Deng, Shujun and Zhang, Yang and Chen, Xinyi and Zhang, Huihui and Yuan, Siming and Tang, Liqin},
title = {Berberine Inhibits Migration and Apoptosis of Rat Podocytes in Diabetic Nephropathy via the Novel lncRNA LOC102549726 Related Pathway},
journal = {Phytotherapy Research},
year = {2025},
doi = {10.1002/ptr.8452}
}
EUVIMED